The role of secondary cytoreductive surgery (SCS) in the treatment of recurrent ovarian cancer (ROC) has been widely increased in recent years, especially in trying to improve the quality of life of these patients by utilising a minimally-invasive (MI) approach. However, surgery in previously-treated patients may be challenging, and patient selection and surgical planning are crucial. Unfortunately, at the moment, validated criteria to select patients for MI-SCS are not reported, and no predictors of its feasibility are currently available, probably due to the vast heterogeneity of recurrence patterns. The aim of this narrative review is to describe the role of secondary cytoreductive surgery and, in particular, minimally-invasive procedures, in ROC, analyzing patient selection, outcomes, criticisms, and future perspectives.
近年来，二次肿瘤细胞减灭术在复发性卵巢癌治疗中的作用日益凸显，尤其通过采用微创手术方式以改善患者生活质量。然而，对既往接受过治疗的患者实施手术存在挑战，患者筛选与手术规划至关重要。目前由于复发模式的高度异质性，尚未建立经验证的微创二次肿瘤减灭术患者选择标准，亦缺乏可行性预测指标。本文旨在通过系统分析患者选择、临床结局、现存争议及未来展望，阐述二次肿瘤细胞减灭术特别是微创手术在复发性卵巢癌治疗中的价值。
Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer
肿瘤(癌症)患者之家